Psoriatic arthritis secondary prevention

Jump to navigation Jump to search

Psoriatic arthritis Microchapters


Patient Information


Historical Perspective




Differentiating Psoriatic arthritis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy

Surgical Therapy

Primary prevention

Secondary prevention

Future or Investigational Therapies

Case Studies

Case #1

Psoriatic arthritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Psoriatic arthritis secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriatic arthritis secondary prevention

CDC on Psoriatic arthritis secondary prevention

Psoriatic arthritis secondary prevention in the news

Blogs onPsoriatic arthritis secondary prevention

Directions to Hospitals Treating Rheumatoid arthritis

Risk calculators and risk factors for Psoriatic arthritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]


Essential measures for the secondary prevention of psoriatic arthritis include calcium and vitamin D supplementation to prevent drug associated osteoporosis. To decrease the risk of cardiovascular complications and to prevent recurrent episodes effective measures include exercise, smoking cessation, and dietary control.

Secondary prevention


  1. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (August 2017). "2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis". Arthritis Rheumatol. 69 (8): 1521–1537. doi:10.1002/art.40137. PMID 28585373.
  2. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). "Assessment of patients with psoriatic arthritis: a review of currently available measures". Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.
  3. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (January 2017). "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update". Ann. Rheum. Dis. 76 (1): 17–28. doi:10.1136/annrheumdis-2016-209775. PMID 27697765.

Template:WH Template:WS